Brief: Fate Therapeutics Announces Preclinical Publication Highlighting Derivation Of Cd8αβ T Cells From Tcr-Car+ Induced Pluripotent Stem Cells
09/08/2022 15:09
Aug 9 (Reuters) - Fate Therapeutics Inc FATE.O :
* FATE THERAPEUTICS ANNOUNCES PRECLINICAL PUBLICATION
HIGHLIGHTING
DERIVATION OF CD8ΑΒ T CELLS FROM TCR-CAR+ INDUCED PLURIPOTENT
STEM CELLS
Source text for Eikon: ID:nGNX1gT9Fg
Further company coverage: FATE.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Fate Therapeutics
See all newsBrief: Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial Of FT819 For The Treatment Of Lupus Nephritis
Fate Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Fate Therapeutics Q2 loss narrows as expenses fall, revenue rises
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview
Fate Therapeutics Inc expected to post a loss of 27 cents a share - Earnings Preview